Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Stephanie A. Halasohoris"'
Autor:
Kei Amemiya, Jennifer L. Dankmeyer, Sarah L. Keasey, Sylvia R. Trevino, Michael M. Wormald, Stephanie A. Halasohoris, Wilson J. Ribot, David P. Fetterer, Christopher K. Cote, Patricia L. Worsham, Jeffrey J. Adamovicz, Robert G. Ulrich
Publikováno v:
Antibodies, Vol 9, Iss 3, p 37 (2020)
Plague is a zoonotic disease that is caused by Yersinia pestis. Monoclonal antibodies (mAbs) that bind to the V-antigen, a virulence factor that is produced by Y. pestis, can passively protect mice from plague. An analysis of protective mAbs that bin
Externí odkaz:
https://doaj.org/article/673628452d76476886124e3319433074
Autor:
Laszlo Otvos Jr., Eszter Ostorhazi, Dora Szabo, Steven D. Zumbrun, Lynda L. Miller, Stephanie A. Halasohoris, Puvi D. Desai, Sharon M. Int Veldt, Carl N. Kraus
Publikováno v:
Frontiers in Chemistry, Vol 6 (2018)
As monotherapy, modified proline-rich antimicrobial peptides (PrAMPs) protect animals from experimental bacteremia in a dose-dependent manner. We evaluated the in vitro synergy of a modified PrAMP, A3-APO, a dimer, previously shown to inhibit the 70
Externí odkaz:
https://doaj.org/article/f79604ed68b04feeb322f7ee2debeb9b
Autor:
Sandra McCurdy, Stephanie A Halasohoris, Ashley L Babyak, Sanae Lembirik, Randall Hoover, Mark Hickman, Jennifer Scarff, Christopher P Klimko, Christopher K Cote, J Matthew Meinig
Publikováno v:
Journal of Antimicrobial Chemotherapy. 78:810-816
ObjectivesTo evaluate the in vitro activity and in vivo efficacy of delafloxacin against Bacillus anthracis, the causative agent of anthrax.MethodsMICs were obtained according to CLSI guidelines for 30 virulent isolates and 14 attenuated antibiotic-r
Autor:
Sailaja Puttagunta, Steven I Aronin, Michael Dunne, Stephanie A Halasohoris, Ashley Babyak, Mary K Hourihan, James M Meinig
Publikováno v:
Open Forum Infectious Diseases. 9
Background Sulopenem is a thiopenem β-lactam antibiotic being developed for the treatment of infections caused by multi-drug resistant bacteria. Sulopenem is available as intravenous and oral pro-drug formulations, and its activity aligns with the m
Publikováno v:
Antimicrobial Agents and Chemotherapy
The in vitro activity and in vivo efficacy of delafloxacin were evaluated against the causative pathogen of melioidosis, Burkholderia pseudomallei. Delafloxacin MICs were determined by broth microdilution according to CLSI guidelines for 30 isolates
Autor:
Sarah V. Harding, Stephanie A. Halasohoris, Purvi D. Desai, Steven D. Zumbrun, Lynda L. Miller, Mark I. Richards, P. Russell, Christine Bentley, Kay B. Barnes
Publikováno v:
Antimicrobial Agents and Chemotherapy. 63
This study investigated the in vitro activity of finafloxacin against panels of the biodefence pathogens. Broth microdilution assays were performed at neutral and acidic pH, to determine the effectiveness of the antibiotics in conditions typical of a
Autor:
Kay B, Barnes, Steven D, Zumbrun, Stephanie A, Halasohoris, Purvi D, Desai, Lynda L, Miller, Mark I, Richards, Paul, Russell, Christine, Bentley, Sarah V, Harding
Publikováno v:
Antimicrobial Agents and Chemotherapy
This study investigated the in vitro activity of finafloxacin against bacterial strain panels of the biodefense pathogens. Broth microdilution assays were performed at neutral and acidic pH to determine the effectiveness of the antibiotics under cond
Autor:
Michael Dunne, Steven I Aronin, Stephanie A Halasohoris, Lisa M Pysz, Sanae Lembirik, James M Meinig
Publikováno v:
Open Forum Infectious Diseases. 8:S628-S628
Background Sulopenem is a thiopenem β-lactam antibiotic being developed for the treatment of infections caused by multi-drug resistant bacteria. Sulopenem possesses potent activity against species of the Enterobacterales that encode ESBLs or AmpC-ty
Autor:
Jeffrey J. Adamovicz, Kei Amemiya, Stephanie A. Halasohoris, Sylvia R. Trevino, Jennifer L. Dankmeyer, Michael M. Wormald, Sarah Keasey, Robert G. Ulrich, Patricia L. Worsham, David P Fetterer, Christopher K. Cote, Wilson J. Ribot
Publikováno v:
Antibodies
Volume 9
Issue 3
Antibodies, Vol 9, Iss 37, p 37 (2020)
Volume 9
Issue 3
Antibodies, Vol 9, Iss 37, p 37 (2020)
Plague is a zoonotic disease that is caused by Yersinia pestis. Monoclonal antibodies (mAbs) that bind to the V-antigen, a virulence factor that is produced by Y. pestis, can passively protect mice from plague. An analysis of protective mAbs that bin